A Dose-escalating Pilot Study of Orelabrutinib in Combination With Rituximab, Methotrexate and Dexamethasone for Newly-diagnosed Primary Central Nervous System Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Dexamethasone (Primary) ; Methotrexate (Primary) ; Orelabrutinib (Primary) ; Rituximab (Primary)
Indications Diffuse large B cell lymphoma
Focus Adverse reactions
Acronyms ORMD2021

18 Oct 2024 Planned End Date changed from 30 Sep 2024 to 30 Sep 2025.
30 Oct 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2024.
30 Oct 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com